Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Postmenopausal Women ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open Label Phase ◽

Er Positive

Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer (Chloe trial)

Annals of Oncology ◽

10.1093/annonc/mdx365.076 ◽

2017 ◽

Vol 28 ◽

pp. v104

Author(s):

T. Shien ◽

A. Shimomura ◽

Y. Uemura ◽

H. Kato ◽

M. Kitada ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Menopausal Women ◽

Open Label Phase ◽

Post Menopausal

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.309 ◽

2018 ◽

Vol 29 ◽

pp. viii102

Author(s):

P. Krivorotko ◽

B. Karaszewska ◽

S. Chan ◽

M. Wieczorek-Rutkowska ◽

T. Sarosiek ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps120 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS120-TPS120

Author(s):

H. L. Gomez ◽

S. P. Neciosup ◽

Y. Neron do Nascimento ◽

G. Ismael ◽

C. H. Barrios

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

328P Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.430 ◽

2020 ◽

Vol 31 ◽

pp. S376

Author(s):

S. Saji ◽

N. Taira ◽

S. Morita ◽

M. Kitada ◽

T. Takano ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Endocrine Therapy ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Open Label ◽

Patient Reported ◽

Open Label Phase ◽

Er Positive

5067 Increased overall response rate to capecitabine in different patient subgroups: results of an open-label phase II study in pretreated metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70959-0 ◽

2009 ◽

Vol 7 (2) ◽

pp. 280

Author(s):

P. Reichardt ◽

G. von Minckwitz ◽

P. Thuss-Patience

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Overall Response Rate ◽

Response Rate ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open Label Phase ◽

Patient Subgroups

An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1127 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1127-1127 ◽

Cited By ~ 1

Author(s):

C. B. Brezden ◽

G. Cantin ◽

J. Younus ◽

L. C. Panasci ◽

P. Klimo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Annals of Oncology ◽

10.1093/annonc/mdz100.001 ◽

2019 ◽

Vol 30 ◽

pp. iii47 ◽

Cited By ~ 2

Author(s):

J. Huober ◽

K. Ribi ◽

P. Weder ◽

Q. Li ◽

L. Vanlemmens ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71443-5 ◽

2011 ◽

Vol 47 ◽

pp. S330 ◽

Cited By ~ 25

Author(s):

S. Hurvitz ◽

L. Dirix ◽

J. Kocsis ◽

L. Gianni ◽

J. Lu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

5062 Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70954-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 279

Author(s):

R. Ratti ◽

Z. Coccorullo ◽

D. Guarneri ◽

G. Addamo ◽

G. Colloca ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Er Positive ◽

Post Menopausal

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

10.1158/1538-7445.sabcs18-pd1-10 ◽

2019 ◽

Cited By ~ 1

Author(s):

WR Parulekar ◽

AA Joy ◽

K Gelmon ◽

M Mates ◽

C Desbiens ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive